EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
EyePoint Pharmaceuticals (NASDAQ: EYPT), a company focused on developing therapeutics for serious retinal diseases, has announced its participation in four upcoming investor conferences in November and December 2024. The company will participate in Guggenheim's Inaugural Healthcare Innovation Conference (Nov 11), UBS Global Healthcare Conference (Nov 13), Jefferies London Healthcare Conference (Nov 19), and BTIG 4th Annual Ophthalmology Day (Dec 2). Each event will feature either a fireside chat or corporate presentation format. Live webcasts and replays will be available through the Investors section of EyePoint's website.
EyePoint Pharmaceuticals (NASDAQ: EYPT), un'azienda focalizzata nello sviluppo di terapie per gravi malattie retiniche, ha annunciato la sua partecipazione a quattro conferenze per investitori che si terranno a novembre e dicembre 2024. L'azienda parteciperà alla Inaugural Healthcare Innovation Conference di Guggenheim (11 novembre), alla UBS Global Healthcare Conference (13 novembre), alla Jefferies London Healthcare Conference (19 novembre) e al BTIG 4th Annual Ophthalmology Day (2 dicembre). Ogni evento presenterà un formato di conversazione informale o di presentazione aziendale. Le dirette web e le registrazioni saranno disponibili nella sezione Investitori del sito web di EyePoint.
EyePoint Pharmaceuticals (NASDAQ: EYPT), una empresa centrada en el desarrollo de terapias para enfermedades retinianas graves, ha anunciado su participación en cuatro conferencias para inversores que se llevarán a cabo en noviembre y diciembre de 2024. La empresa participará en la Inaugural Healthcare Innovation Conference de Guggenheim (11 de noviembre), en la UBS Global Healthcare Conference (13 de noviembre), en la Jefferies London Healthcare Conference (19 de noviembre) y en el BTIG 4th Annual Ophthalmology Day (2 de diciembre). Cada evento contará con un formato de charla informal o presentación corporativa. Las transmisiones en vivo y las repeticiones estarán disponibles en la sección de Inversores del sitio web de EyePoint.
EyePoint Pharmaceuticals (NASDAQ: EYPT), 심각한 망막 질환에 대한 치료제를 개발하는 데 중점을 둔 회사가 2024년 11월과 12월에 열리는 네 번의 투자자 회의에 참여한다고 발표했습니다. 회사는 Guggenheim의 첫 번째 의료 혁신 회의 (11월 11일), UBS 글로벌 의료 회의 (11월 13일), Jefferies 런던 의료 회의 (11월 19일), 그리고 BTIG 제4회 안과의 날 (12월 2일)에 참여할 예정입니다. 각 이벤트는 화상 대화 또는 기업 프레젠테이션 형식을 특징으로 합니다. EyePoint 웹사이트의 투자자 섹션을 통해 라이브 웹캐스트 및 재생이 제공됩니다.
EyePoint Pharmaceuticals (NASDAQ: EYPT), une entreprise axée sur le développement de thérapies pour des maladies rétiniennes graves, a annoncé sa participation à quatre conférences d'investisseurs à venir en novembre et décembre 2024. L'entreprise participera à la Inaugural Healthcare Innovation Conference de Guggenheim (11 novembre), à la Conférence mondiale sur la santé de UBS (13 novembre), à la Conférence sur la santé de Jefferies à Londres (19 novembre) et à la 4ème Journée annuelle de l'ophtalmologie de BTIG (2 décembre). Chaque événement comportera un format de discussion informelle ou de présentation d'entreprise. Des webinaires en direct et des rediffusions seront disponibles dans la section Investisseurs du site Web d'EyePoint.
EyePoint Pharmaceuticals (NASDAQ: EYPT), ein Unternehmen, das sich auf die Entwicklung von Therapeutika für schwerwiegende Netzhauterkrankungen konzentriert, hat seine Teilnahme an vier bevorstehenden Investorenkonferenzen im November und Dezember 2024 angekündigt. Das Unternehmen wird an der Inaugural Healthcare Innovation Conference von Guggenheim (11. November), der UBS Global Healthcare Conference (13. November), der Jefferies London Healthcare Conference (19. November) und dem BTIG 4. Annual Ophthalmology Day (2. Dezember) teilnehmen. Jede Veranstaltung wird entweder im Format eines informellen Gesprächs oder einer Unternehmenspräsentation durchgeführt. Live-Webcasts und Wiederholungen werden im Bereich für Investoren auf der Website von EyePoint verfügbar sein.
- None.
- None.
WATERTOWN, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that company management will participate at the following upcoming conferences:
- Guggenheim's Inaugural Healthcare Innovation Conference
Forum: Fireside Chat
Date: Monday, November 11, 2024
Time: 2:00 p.m. ET
- UBS Global Healthcare Conference
Forum: Fireside Chat
Date: Wednesday, November 13, 2024
Time: 1:15 p.m. PT
- Jefferies London Healthcare Conference
Forum: Corporate Presentation
Date: Tuesday, November 19, 2024
Time: 8:00 a.m. GMT
- BTIG 4th Annual Ophthalmology Day
Forum: Fireside Chat
Date: Monday, December 2, 2024
Time: 10:00 a.m. ET
A live webcast and subsequent archived replay of each presentation may be accessed via the Investors section of the Company website at www.eyepointpharma.com.
About EyePoint Pharmaceuticals
EyePoint Pharmaceuticals (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E™ technology for sustained intraocular drug delivery. The Company’s lead product candidate, DURAVYU™ (f/k/a EYP-1901), is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with bioerodible Durasert E™. DURAVYU is presently in Phase 3 global, pivotal clinical trials as a sustained delivery treatment for wet AMD, the leading cause of vision loss among people 50 years of age and older in the United States, and in a Phase 2 clinical trial in DME. EyePoint expects full topline data from the Phase 2 clinical trial in DME in Q1 2025 and topline data from both Phase 3 pivotal trials in wet AMD in 2026.
Pipeline programs include EYP-2301, a TIE-2 agonist, razuprotafib, formulated in Durasert E™ to potentially improve outcomes in serious retinal diseases. The proven Durasert® drug delivery technology has been safely administered to thousands of patient eyes across four U.S. FDA approved products. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.
Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.
DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.
Investors:
Christina Tartaglia
Precision AQ (formerly Stern IR)
Direct: 212-698-8700
christina.tartaglia@precisionaq.com
Media Contact:
Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com
FAQ
What investor conferences will EyePoint Pharmaceuticals (EYPT) attend in November 2024?
When is EyePoint Pharmaceuticals (EYPT) presenting at the BTIG Ophthalmology Day 2024?
How can investors watch EyePoint Pharmaceuticals (EYPT) conference presentations?
What type of presentations will EyePoint Pharmaceuticals (EYPT) give at the 2024 conferences?
